Fig. 4
The survival analysis of ccRCC patients for the expressions of PRMT1 and ZEB1 in cancer cells, tumor grade and stage (a-d) and qRT-PCR analysis of PRMT1 in ccRCC (E-H). (a-b) Cancer-specific survival rates, revealed by Kaplan-Meier survival analysis, were higher in patients whose cancer cells were positive for both PRMT1 and ZEB1, than those who were negative for both of the markers, (c) Cancer-specific survival rate was lower in patients with high-grade carcinomas, when compared to the patients with low-grade carcinomas, (d) Cancer-specific survival rate was lower in patients with high stage tumors, in comparison to the patients with low stage tumor disease and partial nephrectomy; (e) mRNA PRMT1 expression was decreased in tumor tissue, related to adjacent non-tumor parenchyma, (f) Relative mRNA PRMT1 expression decrease was observed in high-grade tumors, when compared to low grade tumors; (g) Gradual decrease of mRNA PRMT1 was observed by each increase of tumor stage; (h) The graph illustrates the tendency of mRNA PRMT1 expression level decrease by the increase in tumor size; Relative mRNA expression levels are presented with mean values (+/− 1 SD)